Axis Imaging The Script
The Script ยท Published by Axis Imaging, Melbourne

Monday 16 November 2026

2 stories today

1. Using semaglutide in T2D with CKD, including PBS access

You know the patient. Their eGFR is sliding the wrong way, and now they're asking about the jab their neighbour swears by.

In The Medical Republic, endocrinologist Dr Ramy Bishay reviews the trial evidence for semaglutide in type 2 diabetes with CKD. He covers blood sugar control plus kidney and heart outcomes.

He also covers PBS access, which is fair. Picking the drug is the easy bit. Getting it subsidised is where the 15-minute consult goes to die.

The takeaway: Read Bishay's piece before your next diabetic CKD patient asks about semaglutide.

Read the source

2. Do ADHD stimulants raise the risk of psychosis?

Your patient on Vyvanse has seen this year's headlines about stimulants and psychosis, and has booked a long consult. Reassuringly, the risk looks similar to, perhaps lower than, that of oral steroids for asthma flare-ups.

A US study of teens and young adults starting stimulants found about one in 660 developed psychosis within months. Some of that may belong to ADHD itself, which seems to carry extra psychosis risk with or without tablets.

The evidence is still settling. A Finnish study of young people on methylphenidate found no link. In two population studies, psychosis was about twice as common with the amphetamine family, which includes Vyvanse, as with methylphenidate.

Risk is likely higher when stimulants are taken without a script, often as high-dose methamphetamine, smoked or injected. That is a long way from Concerta with breakfast. The authors add that a quick online quiz is not an ADHD assessment, as you've likely told someone waving their results.

The takeaway: Tell worried patients the risk is low, and ask about hallucinations or unusual beliefs at every stimulant review.

Read the source

Also noted

Get tomorrow's issue by email at 6:30am.